晶泰控股发布年度业绩,全年实现营收8.03亿元,同比大幅增长201.25%;期内净利润1.24亿元,同比扭亏为盈,首次实现全年盈利。集团首次实现年度盈利,也成为AI for Science领域首家盈利的港股上市公司。
公开资料显示,2025年,晶泰控股继续深耕“AI for Science”,在抗体业务迅猛增长的同时,成功拓展了多肽、分子胶、核酸等多模态创新平台,推动了赋能服务及孵化企业创新管线逐步进入验证阶段,而业务上的多点开花,也让持续深化发展自身“AI for Science”平台的晶泰,正式迈入“硬核创新—商业化变现—业绩验证”的价值兑现期。
海量资讯、精准解读,尽在新浪财经APP
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.